Stocklytics Platform
APRE
Aprea Therapeutics
APRE46
$1.63arrow_drop_down1.80%-$0.03
Penny Stock
APRE
APRE46

$1.63

arrow_drop_down1.80%
no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Fundamentals
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

APRE-
US Healthcare Sector-
US Market-
warning

APRE / Market

APRE lose to the US Market which returned 0.03% over the last twenty four hours.
warning

APRE / Healthcare Sector

APRE lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.

Aprea Therapeutics (APRE) Statistics

APRE stock statistics provide insight into the performance of Aprea Therapeutics Inc (APRE) in the stock market. These statistics help investors gauge the company's financial health and make informed investment decisions. Some key stock statistics include the stock's price, trading volume, market capitalization, and price-to-earnings ratio. These metrics can be compared to industry benchmarks and historical data to assess the stock's relative strength and valuation. By analyzing APRE's stock statistics, investors can gain valuable insights into the company's performance and potential for growth.
Aprea Therapeutics Inc (APRE) valuation metrics are used to determine the intrinsic value of the company's stock. These metrics include price-to-earnings ratio (P/E ratio), price-to-sales ratio (P/S ratio), and price-to-book ratio (P/B ratio). Valuation metrics provide investors with a way to assess whether a stock is overvalued or undervalued. In the case of APRE, valuation metrics can help investors evaluate the company's current stock price in relation to its earnings, sales, and book value. By analyzing these metrics, investors can make more informed decisions about whether to buy, sell, or hold APRE stock.
add Aprea Therapeutics  to watchlist

Keep an eye on Aprea Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Aprea Therapeutics (APRE) stock's performance compared to its sector and the market over the past year?

Over the past year, Aprea Therapeutics (APRE) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Aprea Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Aprea Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Aprea Therapeutics (APRE) stock?

The PE ratio for Aprea Therapeutics (APRE) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Aprea Therapeutics (APRE) stock?

The Earnings Per Share (EPS) for Aprea Therapeutics (APRE), calculated on a diluted basis, is -$2.8. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Aprea Therapeutics (APRE) stock?

The operating margin for Aprea Therapeutics (APRE) is -1.16K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Aprea Therapeutics (APRE) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Aprea Therapeutics (APRE) is -$14.75M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Aprea Therapeutics (APRE) have?

Aprea Therapeutics (APRE) has a total debt of $0. The net debt, which accounts for cash and cash equivalents against the total debt, is -$26.25M.

Take Your Investments to a Whole New Level